Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

ClinicalTrials.gov ID: NCT07195695

Public ClinicalTrials.gov record NCT07195695. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 11:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations. Eligible participants must have undergone curative-intent surgery and received guideline-appropriate perioperative systemic therapy, either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomized 1:1 to receive zongertinib or standard of care, which may consist of approved adjuvant immunotherapy or active surveillance, based on local practice guidelines. The main purpose of the study is to determine whether zongertinib can prolong disease-free survival compared to standard treatment. Safety and patient-reported outcomes are also assessed.

Study identification

NCT ID: NCT07195695
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Boehringer Ingelheim; Industry
Enrollment: 400 participants

Conditions and interventions

Conditions

Non-small Cell Lung Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 15, 2026
Primary completion: Feb 25, 2032
Completion: Sep 1, 2036
Last update posted: Sep 2, 2026

2026 – 2036

United States locations

U.S. sites: 27
U.S. states: 14
U.S. cities: 24

Facility	City	State	ZIP	Site status
ClinRé 001-022 (Premier Cancer Care and Infusion Center)	Fresno	California	93710	Recruiting
OPN Healthcare, Inc.	Glendale	California	91203	Recruiting
University of California Irvine	Orange	California	92868	Not yet recruiting
Sutter Health	Roseville	California	95661	Not yet recruiting
University of California San Francisco	San Francisco	California	94158	Recruiting
Sarcoma Oncology Center	Santa Monica	California	90403	Recruiting
University of California Los Angeles	Santa Monica	California	90404	Recruiting
Northern California Kaiser Permanente	Vallejo	California	94589	Not yet recruiting
George Washington University Cancer Center	Washington D.C.	District of Columbia	20037	Not yet recruiting
Mid Florida Hematology and Oncology Center	Orange City	Florida	32763	Recruiting
Piedmont Cancer Institute	Atlanta	Georgia	30318	Recruiting
Northwest Georgia Oncology Centers	Marietta	Georgia	30060	Recruiting
Saint Alphonsus Regional Medical Center - Boise	Boise	Idaho	83706	Not yet recruiting
Northwestern University	Chicago	Illinois	60611	Not yet recruiting
University of Illinois Hospital and Health Sciences System	Chicago	Illinois	60612	Recruiting
Duly Health and Care - Lisle	Lisle	Illinois	60532	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Cancer Care Specialists	Reno	Nevada	89511	Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health	New York	New York	10016	Recruiting
Memorial Sloan-Kettering Cancer Center	New York	New York	10065	Recruiting
Levine Cancer Institute	Charlotte	North Carolina	28204	Not yet recruiting
Durham VA Health Care System	Durham	North Carolina	27705	Not yet recruiting
Providence Cancer Institute	Portland	Oregon	97213	Recruiting
Hendrick Health	Abilene	Texas	79601	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Not yet recruiting
Community Cancer Trials of Utah	Ogden	Utah	84405	Recruiting
Virginia Cancer Specialists, PC	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 175 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07195695, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 2, 2026 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07195695 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →